QGEN QIAGEN N.V.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1015820 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY5.7%
TTM net income YoY408.3%
TTM EPS YoY424.3%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR0.1%
Margins
Gross margin62.2%
Operating margin22.3%
Net margin20.3%
FCF margin21.7%
EBITDA margin31.6%
Returns
ROE11.6%
ROA7.1%
ROIC (approx.)9.1%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets39.9%
Debt / equity0.44x
Current ratio3.90x
Interest coverage14.01x
Cash quality & payout
Operating cash flow / net income1.54x
Accruals ratio-3.8%
Payout ratio12.8%
Capex / revenue9.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.09B | $1.98B |
| Cost of revenue | $790.50M | $1.01B |
| Gross profit | $1.30B | $967.35M |
| R&D expense | $187.52M | $193.49M |
| SG&A expense | $125.68M | $113.43M |
| Operating income | $465.85M | $97.71M |
| Interest expense | $33.26M | $43.84M |
| Pretax income | $490.26M | $121.15M |
| Income tax | $65.39M | $37.56M |
| Net income | $424.88M | $83.59M |
| EBITDA | $659.60M | $300.98M |
| EPS (basic) | 1.96 | 0.38 |
| EPS (diluted) | 1.94 | 0.37 |
| Dividends declared per share | 0.25 | — |
| Weighted avg. shares (diluted) | 218.88M | 224.72M |
| Balance sheet | ||
| Cash & equivalents | $839.00M | $663.55M |
| Short-term investments | $259.91M | $489.44M |
| Receivables | $402.61M | $349.28M |
| Inventory | $301.89M | $279.26M |
| Current assets | $2.00B | $1.96B |
| PP&E, net | $923.95M | $753.61M |
| Goodwill | $2.70B | $2.43B |
| Intangibles | $386.43M | $303.81M |
| Total assets | $6.28B | $5.69B |
| Current liabilities | $512.14M | $1.04B |
| Short-term debt | $0 | $551.88M |
| Long-term debt | $1.65B | $839.66M |
| Total debt | $1.65B | $1.39B |
| Total liabilities | $2.50B | $2.12B |
| Shareholders' equity | $3.78B | $3.57B |
| Net debt | $815.42M | $727.99M |
| Cash flow statement | ||
| Operating cash flow | $654.33M | $673.55M |
| Capital expenditure | $201.05M | $167.17M |
| Free cash flow | $453.28M | $506.38M |
| Investing cash flow | -$305.28M | -$249.23M |
| Financing cash flow | -$178.98M | -$422.90M |
| Depreciation & amortization | $193.75M | $203.27M |
| Stock-based compensation | $50.40M | $43.63M |
| Dividends paid | $54.24M | $0 |
| Share buybacks | $280.09M | $292.10M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.